WP2 – Data management, sustainability, and analysis

Building on the strong basis that PRISM has provided, PRISM 2 will focus on statistical analyses solidifying the PRISM approach into establishing reproducible and generalisable biomarkers that allow confident stratification of patients and advanced data management towards generating a sustainable resource for future utility beyond the funding period of the project. These biomarkers are the endpoint measures from the methods selected on the basis of the PRISM study to assess social functioning (total SFS score and BEHAPP digital measure of social functioning) measure DMN integrity (EEG, fMRI and DTI endpoints) and are presented in the Excellence section of the project plan. These biomarkers will be derived from both the unimodal and multimodal analyses, as described in this work package. Specific objectives:

To develop and implement a data management and sustainability plan and provide a mechanism for effective external use of data and biobank materials. We will augment the PRISM data management plan to incorporate procedures detailing continued data governance beyond the end of the PRISM & PRISM 2 projects (Task 1). According to our sustainability roadmap, through BRAIN Commons we will provide a mechanism for data accessibility to both consortium members and other qualified researchers extending beyond the duration of PRISM 2. This will be described in a data sustainability plan. Data anonymization and access limitations will be implemented in accordance with the EU General Data Protection Regulation (GDPR).
To test the level of reproducibility of the transdiagnostic and pathophysiological relationship between Default Mode Network (DMN) integrity and social dysfunction in schizophrenia (SZ) and Alzheimer disease (AD) and its potential to generalise to Major Depressive Disorders (MDD). Analyses on data obtained from newly assessed SZ and AD patients in WP3 will inform about reproducibility, while inclusion of MDD patients in WP3 will establish the generalisability of the selected biomarkers.
To test the causality of DMN integrity on sociability in large-scale, publicly available population-based samples using Mendelian randomization.

The PRISM 2 project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 101034377. The JU receives support from the European Union’s Horizon 2020 research and innovation programme, EFPIA, and Cohen Veterans Bioscience (CVB). The website reflects only the authors' views and IMI JU, EFPIA, CVB, and the European Commission are not responsible for any use that may be made of the information it contains.